ALGBE Fundamental Analysis - GLOBAL BIOENERGIES SA

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALGBE. ALGBE was compared to 69 industry peers in the Chemicals industry. Both the profitability and financial health of ALGBE have multiple concerns. ALGBE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGBE has reported negative net income.

ALGBE had a negative operating cash flow in the past year.

ALGBE had negative earnings in each of the past 5 years.

ALGBE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ALGBE has a worse Return On Assets (-60.73%) than 92.75% of its industry peers.

With a Return On Equity value of -346.31%, ALGBE is not doing good in the industry: 91.30% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-60.73%
ROE	-346.31%
ROIC	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)-195.4%

ROE(5y)-183.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALGBE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGBE does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALGBE has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALGBE has more shares outstanding

The debt/assets ratio for ALGBE is higher compared to a year ago.

2.2 Solvency

ALGBE has an Altman-Z score of -2.51. This is a bad value and indicates that ALGBE is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.51, ALGBE is doing worse than 88.41% of the companies in the same industry.

ALGBE has a Debt/Equity ratio of 2.78. This is a high value indicating a heavy dependency on external financing.

ALGBE has a worse Debt to Equity ratio (2.78) than 91.30% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.78
Debt/FCF	N/A
Altman-Z	-2.51

ROIC/WACCN/A

WACC4.82%

2.3 Liquidity

A Current Ratio of 2.86 indicates that ALGBE has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 2.86, ALGBE belongs to the top of the industry, outperforming 84.06% of the companies in the same industry.

A Quick Ratio of 2.73 indicates that ALGBE has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 2.73, ALGBE belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.86
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.31% over the past year.

Looking at the last year, ALGBE shows a very negative growth in Revenue. The Revenue has decreased by -88.90% in the last year.

Measured over the past years, ALGBE shows a very strong growth in Revenue. The Revenue has been growing by 25.15% on average per year.

EPS 1Y (TTM)33.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.52%

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.9%

Revenue growth 5Y25.15%

Sales Q2Q%-85.13%

3.2 Future

The Earnings Per Share is expected to decrease by -5.13% on average over the next years.

The Revenue is expected to grow by 0.48% on average over the next years.

EPS Next Y22.81%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGBE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGBE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ALGBE's earnings are expected to decrease with -5.13% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALGBE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLOBAL BIOENERGIES SA

EPA:ALGBE (10/17/2025, 7:00:00 PM)

0.026

+0 (+0.39%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)10-01 2025-10-01

Earnings (Next)02-02 2026-02-02/amc

Inst Owners1.07%

Inst Owner ChangeN/A

Ins Owners2.68%

Ins Owner ChangeN/A

Market Cap472.42K

Analysts84.44

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.31
P/FCF	N/A
P/OCF	N/A
P/B	0.28
P/tB	0.29
EV/EBITDA	N/A

EPS(TTM)-0.32

EYN/A

EPS(NY)-0.23

Fwd EYN/A

FCF(TTM)-0.44

FCFYN/A

OCF(TTM)-0.41

OCFYN/A

SpS0.02

BVpS0.09

TBVpS0.09

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-60.73%
ROE	-346.31%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)-195.4%

ROE(5y)-183.82%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score0

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	2.78
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.66%
Cap/Sales	129.34%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.86
Quick Ratio	2.73
Altman-Z	-2.51

F-Score0

WACC4.82%

ROIC/WACCN/A

Cap/Depr(3y)101.02%

Cap/Depr(5y)112%

Cap/Sales(3y)139.76%

Cap/Sales(5y)838.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)33.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.52%

EPS Next Y22.81%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.9%

Revenue growth 5Y25.15%

Sales Q2Q%-85.13%

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y29.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year29.13%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y3.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.94%

OCF growth 3YN/A

OCF growth 5YN/A

GLOBAL BIOENERGIES SA (ALGBE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens